Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...
Over one third of patients with giant cell arteritis exhibit vascular inflammation even after receiving treatment with tocilizumab and glucocorticoids for at least 6 months, which suggests the ...
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback